13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001381843
Total reported value
$371.7M
$371.7M
38 檔
2.6%
At the close of Q3 2025, Atle Fund Management AB disclosed equity holdings valued at approximately $371.7M, spread across 38 reported holdings.
In Q3 2025, Atle Fund Management AB displayed an active expansion posture, initiating 3 new positions and adding to 27 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 11.19% | +0.95% | -3.81% | |
| 2 | ABBV | Abbvie Inc | Stock-Healthcare | 8.40% | +1.00% | +5.95% | |
| 3 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 5.67% | +0.77% | +16.10% | |
| 4 | MRK | Merck & Co. Inc. | Stock-Healthcare | 5.32% | -0.85% | +15.62% | |
| 5 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 5.18% | -0.91% | +11.87% | |
| 6 | ONC | Beone Medicines Ltd-adr | Stock-Other | 4.07% | -1.22% | +24.39% | |
| 7 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.57% | -1.34% | +5.58% | |
| 8 | COR | Cencora Inc | Stock-Healthcare | 3.52% | +0.24% | -9.08% | |
| 9 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.47% | -0.41% | +6.19% | |
| 10 | GILD | Gilead Sciences Inc | Stock-Healthcare | 3.42% | -0.74% | +6.84% | |
| 11 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.33% | -1.18% | -31.31% | |
| 12 | SYK | Stryker CORP | Stock-Healthcare | 3.31% | -0.53% | -17.10% | |
| 13 | ALKS | Alkermes plc | Stock-Healthcare | 2.99% | +0.35% | +11.29% | |
| 14 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 2.93% | +0.21% | +109.30% | |
| 15 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.74% | -1.05% | -26.97% | |
| 16 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.70% | +0.15% | -12.45% | |
| 17 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 2.17% | +0.49% | +23.15% | |
| 18 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 2.03% | -0.29% | +18.53% | |
| 19 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.01% | -0.16% | +14.47% | |
| 20 | CAH | Cardinal Health Inc | Stock-Healthcare | 1.87% | -0.03% | +13.06% | |
| 21 | UFPT | Ufp Technologies Inc | Stock-Other | 1.81% | — | +5.03% | |
| 22 | ✓ | Merus N V | Stock-Other | 1.78% | — | -19.85% | |
| 23 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.60% | -0.71% | EXIT | |
| 24 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.57% | +0.75% | +3.74% | |
| 25 | AMGN | Amgen Inc | Stock-Healthcare | 1.53% | -2.81% | EXIT | |
| 26 | DXCM | Dexcom Inc | Stock-Healthcare | 1.35% | +0.45% | — | |
| 27 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.27% | +0.41% | +38.25% | |
| 28 | IRON | Disc Medicine Inc | Stock-Other | 1.19% | -0.17% | +85.34% | |
| 29 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.10% | -0.90% | EXIT | |
| 30 | HRMY | Harmony Biosciences Holdings | Stock-Other | 1.00% | — | +6.72% | |
| 31 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.89% | — | — | |
| 32 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.87% | — | — | |
| 33 | ACLXGBX | Arcellx Inc | Stock-Other | 0.83% | — | — | |
| 34 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.75% | — | — | |
| 35 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.75% | — | +5.81% | |
| 36 | CELC | Celcuity Inc | Stock-Other | 0.72% | -0.72% | — | |
| 37 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.62% | — | — | |
| 38 | JANX | Janux Therapeutics Inc | Stock-Other | 0.48% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NBIX | Neurocrine Biosciences Inc | +2% | +16.10% | Add |
| 2 | BBIO | Bridgebio Pharma Inc | +1.3% | +5.58% | Add |
| 3 | NAMS | NewAmsterdam Pharma Company N.V. | +1.2% | +23.15% | Add |
| 4 | MIRM | Mirum Pharmaceuticals Inc | +1.2% | -12.45% | Add |
| 5 | ✓ | Merus N V | +1.1% | -19.85% | Add |
| 6 | IRTC | Irhythm Holdings Inc | +1.1% | +18.53% | Add |
| 7 | KRYS | Krystal Biotech Inc | +1.1% | +109.30% | Add |
| 8 | ONC | Beone Medicines Ltd-adr | +1.1% | +24.39% | Add |
| 9 | RVMD | Revolution Medicines Inc | +0.7% | +3.74% | Add |
| 10 | CRBP | Corbus Pharmaceuticals Holdi | +0.6% | — | Add |
| 11 | BCAX | Bicara Therapeutics Inc | +0.6% | +38.25% | Add |
| 12 | SLNOEUR | Soleno Therapeutics Inc | +0.4% | +48.42% | Add |
| 13 | AUTL | Autolus Therapeutics PLC | +0.4% | +5.81% | Add |
| 14 | MRK | Merck & Co. Inc. | +0.3% | +15.62% | Add |
| 15 | MREO | Mereo Biopharma Group Pl-adr | +0.2% | — | Add |
| 16 | CAH | Cardinal Health Inc | +0.2% | +13.06% | Add |
| 17 | TMO | Thermo Fisher Scientific Inc | +0.2% | +11.87% | Add |
| 18 | ABBV | Abbvie Inc | +0.2% | +5.95% | Add |
| 19 | ISRG | Intuitive Surgical Inc | +0.1% | +6.19% | Add |
| 20 | EW | Edwards Lifesciences CORP | +0.1% | +14.47% | Add |
| 21 | DXCM | Dexcom Inc | 0% | — | Add |
| 22 | UFPT | Ufp Technologies Inc | -0.1% | +5.03% | Add |
| 23 | JANX | Janux Therapeutics Inc | -0.1% | — | Add |
| 24 | ALKS | Alkermes plc | -0.1% | +11.29% | Add |
| 25 | SMMT | Summit Therapeutics Inc | -0.1% | — | Trim |
| 26 | HRMY | Harmony Biosciences Holdings | -0.3% | +6.72% | Add |
| 27 | COR | Cencora Inc | -0.4% | -9.08% | Trim |
| 28 | GILD | Gilead Sciences Inc | -0.4% | +6.84% | Add |
| 29 | ACLXGBX | Arcellx Inc | -0.5% | — | Trim |
| 30 | SYK | Stryker CORP | -0.5% | -17.10% | Trim |
| 31 | LLY | Eli Lilly & Co | -1.4% | -3.81% | Add |
| 32 | AMGN | Amgen Inc | -2.1% | -42.22% | Trim |
| 33 | VRTX | Vertex Pharmaceuticals Inc | -2.1% | -26.97% | Trim |
| 34 | BSX | Boston Scientific CORP | -2.6% | -31.31% | Trim |
| 35 | UNH | Unitedhealth Group Inc | -4.9% | — | Trim |
| 36 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 37 | IRON | Disc Medicine Inc | — | NEW | New buy |
| 38 | CABA | Cabaletta Bio Inc | — | EXIT | Sold out |
| 39 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 40 | CELC | Celcuity Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Atle Fund Management AB reported a total U.S. public equity portfolio value of $371.7M across 38 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, ABBV, NBIX) accounted for 2.6% of total reported equity market value during Q3 2025.
Top New Position Initiated
IRON
市值: $320.5K
Top Position Liquidated / Trimmed
VRNA
前期市值: $2.2M
During Q3 2025, Atle Fund Management AB's top holdings by market value included LLY (11.2%)、ABBV (8.4%)、NBIX (5.7%). The largest single position, LLY, represented 11.2% of total portfolio value.
In Q3 2025, Atle Fund Management AB made 40 total portfolio adjustments, initiating 3 new buys, adding to 27 positions, trimming 8 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.